IN2014KN00948A - - Google Patents

Info

Publication number
IN2014KN00948A
IN2014KN00948A IN948KON2014A IN2014KN00948A IN 2014KN00948 A IN2014KN00948 A IN 2014KN00948A IN 948KON2014 A IN948KON2014 A IN 948KON2014A IN 2014KN00948 A IN2014KN00948 A IN 2014KN00948A
Authority
IN
India
Prior art keywords
same
tautomer
diastereomer
enantiomer
solvate
Prior art date
Application number
Other languages
English (en)
Inventor
Grayson B Lipford
Charles M Zepp
Original Assignee
Janus Biotherapeutics Inc
Grayson B Lipford
Charles M Zepp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janus Biotherapeutics Inc, Grayson B Lipford, Charles M Zepp filed Critical Janus Biotherapeutics Inc
Publication of IN2014KN00948A publication Critical patent/IN2014KN00948A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN948KON2014 2011-10-04 2012-10-03 IN2014KN00948A (,)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161543082P 2011-10-04 2011-10-04
PCT/US2012/058566 WO2013052550A2 (en) 2011-10-04 2012-10-03 Novel imidazole quinoline-based immune system modulators

Publications (1)

Publication Number Publication Date
IN2014KN00948A true IN2014KN00948A (,) 2015-08-21

Family

ID=48044383

Family Applications (1)

Application Number Title Priority Date Filing Date
IN948KON2014 IN2014KN00948A (,) 2011-10-04 2012-10-03

Country Status (8)

Country Link
US (1) US9873694B2 (,)
EP (1) EP2763677B1 (,)
JP (1) JP2014528449A (,)
AU (1) AU2012318694B2 (,)
CA (1) CA2850932A1 (,)
IL (1) IL231957A0 (,)
IN (1) IN2014KN00948A (,)
WO (1) WO2013052550A2 (,)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CA3031675A1 (en) 2016-07-30 2018-02-08 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
WO2018049089A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
CN110997670B (zh) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
KR102651947B1 (ko) 2017-08-04 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물
KR102849449B1 (ko) 2017-11-14 2025-08-21 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 화합물
CA3085333A1 (en) 2017-12-15 2019-06-20 Bristol-Myers Squibb Company Substituted indole ether compounds
TWI689510B (zh) 2017-12-18 2020-04-01 美商必治妥美雅史谷比公司 4-氮雜吲哚化合物
US11878975B2 (en) 2017-12-19 2024-01-23 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
JP7313354B2 (ja) 2017-12-19 2023-07-24 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物
ES2977657T3 (es) 2017-12-19 2024-08-28 Bristol Myers Squibb Co Compuestos de 6-azaindol
ES2904773T3 (es) 2017-12-20 2022-04-06 Bristol Myers Squibb Co Compuestos de diazaindol
MX2020005513A (es) 2017-12-20 2020-09-03 Bristol Myers Squibb Co Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr).
CN111491918B (zh) 2017-12-20 2023-10-24 百时美施贵宝公司 芳基和杂芳基取代的吲哚化合物
JP7597709B2 (ja) 2018-10-24 2024-12-10 ブリストル－マイヤーズ スクイブ カンパニー 置換インドールおよびインダゾール化合物
WO2020086505A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole dimer compounds
JP2022525216A (ja) * 2019-03-15 2022-05-11 バーディー バイオファーマシューティカルズ インコーポレイテッド 癌の治療のための免疫調節組成物および方法
CN114126713B (zh) 2019-05-09 2023-12-08 百时美施贵宝公司 经取代的苯并咪唑酮化合物
US12448395B2 (en) 2019-10-01 2025-10-21 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
ES2965164T3 (es) 2019-10-04 2024-04-11 Bristol Myers Squibb Co Compuestos de carbazol sustituidos
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
US12077539B2 (en) 2021-03-22 2024-09-03 Incyte Corporation Imidazole and triazole KRAS inhibitors
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
AU2022306671A1 (en) 2021-07-07 2024-01-25 Incyte Corporation Tricyclic compounds as inhibitors of kras
CA3229855A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
US12070455B2 (en) 2021-09-10 2024-08-27 Gilead Sciences, Inc. Thienopyrrole compounds
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
WO2023056421A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
CR20240197A (es) 2021-10-14 2024-08-07 Incyte Corp Compuestos de quinolina como inhibidores de kras

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AR006928A1 (es) 1996-05-01 1999-09-29 Pioneer Hi Bred Int Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69841514D1 (de) 1997-05-07 2010-04-01 Schering Corp Menschliche Toll-Like-Rezeptorproteine, zugehörige Reagenzien und Verfahren
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
JP2002510644A (ja) 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
WO1999056755A1 (en) 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
CN1346350A (zh) 1999-01-22 2002-04-24 依兰制药公司 抑制vla－4介导的白细胞粘着的化合物
JP2003510290A (ja) 1999-09-27 2003-03-18 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激核酸誘導インターフェロンに関する方法
HK1049017A1 (zh) 2000-05-25 2003-04-25 Schering Corporation 人受体蛋白、相关的试剂和方法
CA2457485C (en) 2001-08-17 2012-08-14 Arthur M. Krieg Combination motif immune stimulatory oligonucleotides with improved activity
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
AU2004257149A1 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (TLR) antagonists
JP2008531567A (ja) * 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン化合物および方法
JP5247458B2 (ja) * 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法
CA2647100A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
US8027888B2 (en) * 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US7943771B2 (en) * 2007-01-24 2011-05-17 Chemagis Ltd. Imiquimod production process
CA2675845C (en) * 2007-01-31 2019-03-05 Chongxi Yu Positively charged water-soluble prodrugs of 1h-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
MX2011002264A (es) * 2008-09-10 2011-05-23 Kalypsys Inc Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad.
EP2507237A1 (en) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds

Also Published As

Publication number Publication date
JP2014528449A (ja) 2014-10-27
EP2763677B1 (en) 2020-02-26
WO2013052550A3 (en) 2014-05-15
IL231957A0 (en) 2014-05-28
AU2012318694A1 (en) 2014-05-22
US9873694B2 (en) 2018-01-23
EP2763677A4 (en) 2015-05-20
US20140242121A1 (en) 2014-08-28
CA2850932A1 (en) 2013-04-11
EP2763677A2 (en) 2014-08-13
AU2012318694B2 (en) 2016-12-22
WO2013052550A2 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
IN2014KN00948A (,)
PH12020550552A1 (en) Inhibitors of hepatitis c virus
MY165087A (en) Neprilysin inhibitors
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
PH12013501704A1 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
PH12013501240A1 (en) Neprilysin inhibitors
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
WO2010108074A3 (en) Inhibitors of pi3 kinase
MX2013006802A (es) Inhibidores de neprilisina.
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
MX2013011591A (es) Métodos y composiciones para tratar enfermedades neurodegenerativas.
EP4582424A3 (en) 1,2-naphthoquinone derivative and method for preparing same
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX350746B (es) Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.
MX348393B (es) Polimorfo de rifaximina y proceso para la preparacion del mismo.
PH12017500089B1 (en) Aldosterone synthase inhibitors
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
MX342153B (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
PH12013501055A1 (en) Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
PH12013501054A1 (en) Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
WO2012164055A3 (en) New compounds, synthesis and use thereof in the treatment of pain
HK1231074A1 (en) Neprilysin inhibitors
WO2012008765A3 (ko) 암 치료 또는 예방용 약학 조성물
HK1207862A1 (en) 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions